<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-75939</identifier>
<setSpec>0300-2896</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Chronic thromboembolic pulmonary hypertension: surgical treatment with thromboendarterectomy</dc:title>
<dc:description xml:lang="en">Background and objectivesPulmonary thromboendarterectomy (PTE) is considered the potential curative treatment for chronic thromboembolic pulmonary hypertension (CTEPH). We analysed the results of the PTE application in our institution.Patients and methodsFrom February 1996 to December 2007, 30 patients with CTEPH underwent video-assisted PTE. Preoperative hemodynamic data were: systolic pulmonary artery pressure (SPAP) 87±17mmHg, mean pulmonary artery pressure (MPAP) 51±11mmHg, pulmonary total resistance 1067±485dynes·s·cm&#150;5, pulmonary vascular resistance 873±389dynes·s·cm&#150;5 and cardiac index 2.2±0.5l/min/m2. We analysed the influence of several factors on hospital mortality and survival, and we performed partial analysis of mortality since 2004.ResultsPTE resulted in significant improvements in SPAP (P&lt;0.001), MPAP (P=0.001) and cardiac index (P&lt;0.001). Hospital mortality was 17% (5/30) (95% confidence interval, 6%-35%). From 2004, it dropped to 5% (1/20) (95% confidence interval, 0%-25%). Hospital mortality was influenced by preoperative pulmonary total resistance, preoperative pulmonary vascular resistance, postoperative SPAP, reduction of SPAP, reduction of MPAP, reperfusion pulmonary oedema and residual postoperative pulmonary hypertension (P=0.036; P=0.018;P=0.013; P=0.050; P=0.050; P=0.030; P=0.045). Survival after PTE, including hospital mortality, was 76±9% at 10 years. Through long-term follow-up, functional status (P=0.001), 6min walking distance (P=0.001), end-diastolic right ventricle size (P&lt;0.001), and tricuspid regurgitation (P&lt;0.001) significantly improved.ConclusionsPTE effectively reduces pulmonary hypertension and offers CTEPH patients a substantial improvement in survival and quality of life(AU)</dc:description>
<dc:creator>Blázquez, José Antonio</dc:creator>
<dc:creator>López, María Jesús</dc:creator>
<dc:creator>Pérez, Enrique</dc:creator>
<dc:creator>Escribano, Pilar</dc:creator>
<dc:creator>Cortina, José María</dc:creator>
<dc:creator>Gómez, Miguel Ángel</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">ConclusionesLa TP mejora la hemodinámica pulmonar, prolonga la supervivencia y optimiza el estado funcional de pacientes con HTPTC(AU)</dc:description>
<dc:source>Arch Bronconeumol;45(10): 496-501, oct. 2009. ilus, graf</dc:source>
<dc:identifier>ibc-75939</dc:identifier>
<dc:title xml:lang="es">Hipertensión pulmonar tromboembólica crónica: tratamiento mediante tromboendarterectomía quirúrgica</dc:title>
<dc:subject>^d29315</dc:subject>
<dc:subject>^d7155^s22053</dc:subject>
<dc:subject>^d7155^s22047</dc:subject>
<dc:subject>^d4772</dc:subject>
<dc:subject>^d7155^s22067</dc:subject>
<dc:subject>^d12092^s22009</dc:subject>
<dc:subject>^d8348</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d7155^s22080</dc:subject>
<dc:subject>^d14308</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d4772^s22045</dc:subject>
<dc:subject>^d12092^s22047</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d7155^s22027</dc:subject>
<dc:subject>^d12092^s22027</dc:subject>
<dc:subject>^d12092^s22067</dc:subject>
<dc:type>article</dc:type>
<dc:date>200910</dc:date>
</metadata>
</record>
</ibecs-document>
